JP7411559B2 - Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法 - Google Patents

Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法 Download PDF

Info

Publication number
JP7411559B2
JP7411559B2 JP2020544813A JP2020544813A JP7411559B2 JP 7411559 B2 JP7411559 B2 JP 7411559B2 JP 2020544813 A JP2020544813 A JP 2020544813A JP 2020544813 A JP2020544813 A JP 2020544813A JP 7411559 B2 JP7411559 B2 JP 7411559B2
Authority
JP
Japan
Prior art keywords
antibody
muc1
shows
psmgfr
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514973A (ja
JP2021514973A5 (enExample
Inventor
バンダッド，シンシア
Original Assignee
ミネルバ バイオテクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/062569 external-priority patent/WO2019104306A1/en
Application filed by ミネルバ バイオテクノロジーズ コーポレーション filed Critical ミネルバ バイオテクノロジーズ コーポレーション
Publication of JP2021514973A publication Critical patent/JP2021514973A/ja
Publication of JP2021514973A5 publication Critical patent/JP2021514973A5/ja
Priority to JP2023218543A priority Critical patent/JP7705442B2/ja
Application granted granted Critical
Publication of JP7411559B2 publication Critical patent/JP7411559B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020544813A 2018-02-26 2019-02-26 Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法 Active JP7411559B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023218543A JP7705442B2 (ja) 2018-02-26 2023-12-25 Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862635378P 2018-02-26 2018-02-26
US62/635,378 2018-02-26
US201862640697P 2018-03-09 2018-03-09
US62/640,697 2018-03-09
USPCT/US18/62569 2018-11-27
PCT/US2018/062569 WO2019104306A1 (en) 2017-11-27 2018-11-27 Humanized anti-muc1* antibodies and direct use of cleavage enzyme
US201962791661P 2019-01-11 2019-01-11
US62/791,661 2019-01-11
PCT/US2019/019566 WO2019165421A1 (en) 2018-02-26 2019-02-26 Diagnostic methods using anti-muc1* antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023218543A Division JP7705442B2 (ja) 2018-02-26 2023-12-25 Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法

Publications (3)

Publication Number Publication Date
JP2021514973A JP2021514973A (ja) 2021-06-17
JP2021514973A5 JP2021514973A5 (enExample) 2022-03-07
JP7411559B2 true JP7411559B2 (ja) 2024-01-11

Family

ID=67688578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544813A Active JP7411559B2 (ja) 2018-02-26 2019-02-26 Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法
JP2023218543A Active JP7705442B2 (ja) 2018-02-26 2023-12-25 Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023218543A Active JP7705442B2 (ja) 2018-02-26 2023-12-25 Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法

Country Status (8)

Country Link
US (3) US11976132B2 (enExample)
EP (1) EP3759145A4 (enExample)
JP (2) JP7411559B2 (enExample)
CN (1) CN112272677B (enExample)
AU (2) AU2019225237B2 (enExample)
CA (1) CA3092247A1 (enExample)
IL (1) IL276925A (enExample)
WO (1) WO2019165421A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024045120A (ja) * 2018-02-26 2024-04-02 ミネルバ バイオテクノロジーズ コーポレーション Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
IL294486A (en) * 2020-01-13 2022-09-01 Truebinding Inc Antibodies against gal3 and methods of use
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
JP2023530997A (ja) * 2020-06-19 2023-07-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体
AU2021297535A1 (en) 2020-06-26 2023-02-16 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
GR20200100703A (el) * 2020-11-26 2022-06-08 Icarus Antibodies Ι.Κ.Ε, Μονοκλωνικα αντισωματα εναντι του κορωνοϊου sars-cov-2 και χρησεις αυτων
CN116554317B (zh) * 2022-01-29 2025-02-28 浙江纳米抗体技术中心有限公司 Muc1结合分子及其应用
TW202346330A (zh) 2022-03-18 2023-12-01 美商長典生物晶片股份有限公司 抗豬繁殖與呼吸道綜合症病毒的抗體及其用途
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (en) 2023-08-29 2025-03-06 Minerva Biotechnologies Corporation Bacterial nme7 orthologs and uses thereof
CN117820483B (zh) * 2024-03-01 2024-05-28 北京纳百生物科技有限公司 一种猫n-端脑利钠肽前体蛋白单克隆抗体、检测试纸条及应用
WO2025255276A1 (en) * 2024-06-04 2025-12-11 Fred Hutchinson Cancer Center Anti-whitlow linker binding domains and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9263101A (en) * 2000-09-11 2002-03-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US20100150914A1 (en) 2006-11-09 2010-06-17 Irm Llc Agonist trkb antibodies and uses thereof
JP2015502975A (ja) * 2011-12-22 2015-01-29 ライナット ニューロサイエンス コーポレイション ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法
RU2016144178A (ru) * 2014-04-28 2018-05-10 Медисинал Кемистри Фармасьютикалс, Ко., Лтд. Антитело против muc1 или его антигенсвязывающий фрагмент и его применение
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024045120A (ja) * 2018-02-26 2024-04-02 ミネルバ バイオテクノロジーズ コーポレーション Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法
JP7705442B2 (ja) 2018-02-26 2025-07-09 ミネルバ バイオテクノロジーズ コーポレーション Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法

Also Published As

Publication number Publication date
JP7705442B2 (ja) 2025-07-09
US20200407462A1 (en) 2020-12-31
EP3759145A1 (en) 2021-01-06
AU2019225237A8 (en) 2020-10-15
JP2024045120A (ja) 2024-04-02
JP2021514973A (ja) 2021-06-17
CN112272677A (zh) 2021-01-26
IL276925A (en) 2020-10-29
CN112272677B (zh) 2024-10-29
AU2026201952A1 (en) 2026-04-02
CA3092247A1 (en) 2019-08-29
AU2019225237B2 (en) 2025-12-18
US11976132B2 (en) 2024-05-07
US20250066505A1 (en) 2025-02-27
WO2019165421A1 (en) 2019-08-29
EP3759145A4 (en) 2022-03-09
US12351646B2 (en) 2025-07-08
AU2019225237A1 (en) 2020-09-17
US20240352149A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
JP7705442B2 (ja) Ａｎｔｉ－ｍｕｃｉ＊抗体を用いた診断法
AU2011278562C1 (en) Novel antibody for the diagnosis and/or prognosis of cancer
JP4628365B2 (ja) 免疫組織化学的方法
EP3677910B1 (en) Diagnosing pancreatic cancer using methionyl-trna synthetase and ck19
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
JP6122948B2 (ja) 胃癌の治療のための方法
WO2022154037A1 (ja) がんの予後バイオマーカー
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
CN120265985A (zh) 使用锌指蛋白样1抗体诊断和治疗前列腺癌的方法
HK1262633B (zh) 用於评估癌症发生的风险的组合物和方法
HK1248730B (zh) Igf-1r抗体及其用於癌症诊断的用途

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20211104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220225

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230125

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20230301

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231225

R150 Certificate of patent or registration of utility model

Ref document number: 7411559

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150